8-K filing — Bluejay Diagnostics, Inc. (BJDX)
Filed: 2026-09-08 AccNo: 0001213900-26-098071 Size: 443 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Bluejay Diagnostics shares are trading higher after the company announced a strategic partnership with Lovell Government Services to support the introduction of its products into the federal healthcare market.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Bluejay Diagnostics And Lovell Announce Distribution, Co-Marketing And Strategic Partnership To Support Introduction Of Bluejay’s Products Into U.S. Federal Healthcare Market
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, and
Bluejay Diagnostics Q2 EPS $(1.12) Up From $(5.64) YoY
Bluejay Diagnostics (NASDAQ:BJDX) reported quarterly losses of $(1.12) per share. This is a 80.14 percent increase over losses of $(5.64) per share from the same period last year.